Why is next-generation sequencing used in genomic tumour profiling?

A laboratory analyses genetic material from a tumour sample, often tissue collected during a biopsy or surgery. The test looks for changes in tumour DNA, such as alterations that help cancer cells grow or repair themselves. Testing several genes together can give the oncology team a broader view than checking one change at a time.

A report may identify a change linked with a targeted medicine, suggest that a different treatment approach should be considered, or show that no currently actionable change was found. A result does not by itself prove how a tumour will behave or guarantee that a medicine will work. The meaning depends on the cancer type, sample quality, previous treatment, and the wider clinical picture.

Ask which sample was tested, whether the sample contained enough tumour tissue, and which findings are considered actionable. Discuss whether the result affects treatment choices now, whether another sample or a blood-based test is needed, and whether genetic counselling is appropriate if a finding might be inherited. Keep a copy of the report and ask the team to explain unfamiliar terms before making decisions.

Genomic profiling itself does not usually create an urgent problem, but contact your oncology team promptly if you develop new or worsening symptoms during any treatment chosen after the result, such as breathing difficulty, severe weakness, confusion, persistent vomiting, or a high temperature. Follow the emergency instructions supplied by your treatment centre.

Which tumour changes were found, and which are relevant to my cancer? Could this result change my treatment plan? Does any finding suggest an inherited risk for my relatives? How long will the result remain useful if my cancer changes?